IPS is participating in the Cellicon Valley '21: The Future of Cell and Gene Therapies Virtual Symposium hosted by the University of Pennsylvania's Perelman School of Medicine.
As home to the first FDA-approved cell and gene therapies, Penn and Children’s Hospital of Philadelphia are international leaders who have helped propel Philadelphia into Cellicon Valley, with Penn ranking first among global universities for CAR-T cell patents according to Nature. CAR T represents a turning point in the history of human medicine, a genuine revolution in our approach to the disease within the field of cellular therapy and transplant. The FDA approvals of chimeric antigen receptor (CAR) T cells offer even patients with highly chemo-refractory hematologic malignancies additional treatment options. World experts in cell and gene therapy and have been assembled to discuss the development and implementation of these therapies and to weigh in on current applications, best practices, novel strategies and future developments in this field. Activity format will provide a significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care and understand new strategies to optimize and improve gene and cell therapies. Participants will leave with up-to-date, practical information which will have the immediate clinical application, and an understanding of critical research initiatives that are rapidly driving this field forward, as well as the technical and scientific background on the current state, and where the latest scientific advances may take the field.
Who Should Attend
These activities are intended for both adult and pediatric hematologist-oncologists, medical oncologists, hematologists, hematopathologists, immunologists, immunobiologists, transfusion medicine, researchers, pharmacists, fellows, nurses, nurse practitioners, physician assistants, industry professionals and other healthcare professionals interested in the latest advances in cell and gene therapy. Additionally, patients and their caregivers, family members, advocates and members of the public who may benefit from understanding current innovative approaches to gene and cell therapy are also invited.
Upon completion of this symposium, participants should be able to:
- Identify current application of CAR T-cell therapy including disease indication, accurate patient selection, manufacture, and treatment administration
- List approaches to overcome resistance to monotherapy CAR’s
- Implement guidelines for patient management, and identify causes of toxicities of CAR T-cell therapies including cytokine release syndrome and neurologic toxicity.
- Describe gene delivery and editing for CARs
- Identify the latest targets and technologies for CARs
- Identify the current status of globalization of CAR T-cell therapies and identify principles in ethics of patient access
- Describe current approaches in treatment and supportive care for hematopoietic stem cell transplantation (HSCT) in pediatric patients with nonmalignant conditions
- Identify the latest evidence-based standards in nursing care resulting from the recent advances in cell/gene therapy and transplant
Thursday, May 6, 2021
4:30 pm to 6:00 pm
Friday, May 7, 2021
7:00 am to 4:30 pm EDT